EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Advancing Transthyretin Amyloidosis Drug Development in an Evolving Treatment Landscape: Amyloidosis Forum Meeting Proceedings

Mathew S Maurer iD, Prem Soman iD, Adrian Hernandez iD, Pablo Garcia-Pavia iD, James Signorovitch iD, L J Wei iD, Mazen Hanna iD, Frederick L Ruberg iD, Michelle Kittleson iD, Dhruv Kazi iD, Sharmila Dorbala iD, Kristen Hsu iD und 6 weitere

Advances in Therapy · 2024

DOI: 10.1007/s12325-024-02891-0 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advances in Therapy, 2024. Verfasst von Mathew S Maurer und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Drug Development. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NHLBI NIH HHS, National Institute of Aging.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Hereditary transthyretin amyloidosis (ATTRv, also referred to as hATTR; ORPHA 271861) and wild-type ATTR amyloidosis (ATTRwt; ORPHA 330001) are rare, progressive, systemic protein misfolding disorders with heterogeneous clinical presentations. ATTRv and ATTRwt amyloidosis are characterized by the deposition of amyloid fibrils in multiple organs including the heart, nerves, eyes, and soft tissues. The management of ATTR amyloidosis is complex because of its multisystemic nature and progression despite available treatment options. Morbidity is high and there are many unmet medical needs for patients. While contemporary ATTR amyloidosis cohorts are diagnosed earlier, have lower risk disease and lower mortality compared with the previous era, these advances coupled with the emergence of effective disease-modifying therapies have confounded the design of future prospective clinical trials and interpretation of historical control data. MAIN BODY: The Amyloidosis Forum is a public-private partnership between the US Food and Drug Administration Center for Drug Evaluation and Research and the nonprofit Amyloidosis Research Consortium ( www.arci.org ). This article summarizes proceedings from the 21 June 2023 Amyloidosis Forum on advancing drug development in ATTR amyloidosis in an evolving treatment landscape. The Forum focused on elements of clinical trial design to address these challenges and discussed their strengths and weaknesses from multiple stakeholder perspectives (i.e., patient, sponsor, statistician, clinician, and regulatory authorities). CONCLUSION: Given rapid evolution of natural history in ATTR amyloidosis, the utility of historical control data is limited. Leveraging contemporary real-world data is essential for clinical trial design. Evidence generation from clinical trials should address clinically relevant questions. Key factors in successful trial design must be informed by up-to-date data on natural history, prognostic factors, clinically meaningful thresholds, and sharing available clinical trial data. The Amyloidosis Forum includes the community of patients with ATTR amyloidosis, the physicians who treat them, and the sponsors and regulators who collectively stand ready to support further studies in order to develop novel effective therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid Neuropathies, FamilialDrug DevelopmentHumansBenzoxazolesOligonucleotides

Stichwörter der Autor:innen

Clinical trial designDrug developmentRare diseasesTransthyretin amyloidosis

Substanzen

BenzoxazolestafamidisInotersenOligonucleotides

Autor:innen und Institutionen

  • Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
  • University of Pittsburgh Medical Center, UPMC Heart and Vascular Institute, Cardiac Amyloidosis Center, Pittsburg, PA, USA.
  • Duke University School of Medicine, Duke Clinical Research Center, Durham, NC, USA.
  • Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV, Madrid, Spain.
  • Spanish National Cardiovascular Research Institute (CNIC), Madrid, Spain.
  • Analysis Group, Boston, MA, USA.

ORCID-Profile: Mathew S Maurer, Prem Soman, Adrian Hernandez, Pablo Garcia-Pavia, James Signorovitch, L J Wei, Mazen Hanna, Frederick L Ruberg, Michelle Kittleson, Dhruv Kazi, Sharmila Dorbala, Kristen Hsu, Isabelle Lousada, Rosalyn Adigun, Preston Dunnmon, Jeffery Kelly, Julian Gillmore

Förderung

  • NIA NIH HHS
  • NHLBI NIH HHS
  • National Institute of Aging

Zitieren

APA

Maurer, M. S., Soman, P., Hernandez, A., Garcia-Pavia, P., Signorovitch, J., Wei, L. J., Hanna, M., Ruberg, F. L., Kittleson, M., Kazi, D., Dorbala, S., Hsu, K., Lousada, I., Adigun, R., Dunnmon, P., Kelly, J., Gillmore, J., & Amyloidosis Forum Meeting Panelists (2024). Advancing Transthyretin Amyloidosis Drug Development in an Evolving Treatment Landscape: Amyloidosis Forum Meeting Proceedings. Advances in Therapy. https://doi.org/10.1007/s12325-024-02891-0

Vancouver

Maurer MS, Soman P, Hernandez A, Garcia-Pavia P, Signorovitch J, Wei LJ, et al. Advancing Transthyretin Amyloidosis Drug Development in an Evolving Treatment Landscape: Amyloidosis Forum Meeting Proceedings. Advances in Therapy. 2024. doi:10.1007/s12325-024-02891-0

BibTeX
@article{Maurer2024,
  author = {Maurer, Mathew S and Soman, Prem and Hernandez, Adrian and Garcia-Pavia, Pablo and Signorovitch, James and Wei, L J and Hanna, Mazen and Ruberg, Frederick L and Kittleson, Michelle and Kazi, Dhruv and Dorbala, Sharmila and Hsu, Kristen and Lousada, Isabelle and Adigun, Rosalyn and Dunnmon, Preston and Kelly, Jeffery and Gillmore, Julian and Amyloidosis Forum Meeting Panelists, Amyloidosis Forum Meeting Panelists},
  title = {Advancing Transthyretin Amyloidosis Drug Development in an Evolving Treatment Landscape: Amyloidosis Forum Meeting Proceedings},
  journal = {Advances in Therapy},
  year = {2024},
  doi = {10.1007/s12325-024-02891-0}
}
Kostenlos starten →